HIF

HIF proposes $600 million annual budget to evaluate health impacts

One feature of the HIF that is raising eyebrows is their proposal to
spend $600 million *per year* on assessing health impacts. This is
apparently more than an order of magnitude greater than the entire
budget of NICE. The reference to the $600 million from the HIF book
follows:

Aidan Hollis and Thomas Pogge, The Health Impact Fund, Making New
Medicines Accessible for All, A Report of Incentives for Global Health,
2008

Page 30-32

THE COST OF HEALTH IMPACT ASSESSMENT

Blogging the Washington DC HIF presentation

Yesterday December 1 2008, professors Aidan Hollis and Thomas Pogge presented their Health Impact Fund (HIF) proposal at Georgetown University in Washington, DC.

The meeting convened and moderated by the President of Georgetown University, Jack deGioia, was attended by 50/60 people and was structured with two presentations by the co-authors and a panel discussion by :

Paul Antony, M.D., Chief Medical Officer and Executive Director, PhRMA
Lawrence Gostin, J.D., Associate Dean and Timothy and Linda O’Neill Professor of Global Health Law, Georgetown University Law Center

Pogge and Hollis on the Trade-off between access and incentives

This is a comment on the references to compulsory licensing in the Hollis/Pogge HIF book that are quoted below.

http://www.keionline.org/blogs/2008/11/18/excerpts-from-hif-compulsory-licensing/
Aidan Hollis and Thomas Pogge, The Health Impact Fund, Making New Medicines Accessible for All, A Report of Incentives for Global Health, 2008.

Impact of the HIF on generic industry in developing countries

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”
Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Why the HIF rejected open licensing

In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:

Excerpts from HIF: compulsory licensing

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.

Page 53-54

HIF on the Sanders prize fund bill

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.

Page 105-106

Medical Innovation Prize Act of 2007

HIF on why voluntary licensing of patents is not required

In book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss why voluntary licensing of patents is not required.

Page 22

Voluntary Licensing

HIF on Intellectual Property

Aidan Hollis and Thomas Pogge discuss Intellectual Property and the HIF.*

Intellectual Property

Syndicate content